Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Cancer Metastatic × Irinotecan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 334 Rectal Neoplasms 132 Colonic Neoplasms 132 Stomach Neoplasms 97 Pancreatic Neoplasms 94 Neoplasm Metastasis 72 Neoplasms 62 Esophageal Neoplasms 54 Small Cell Lung Carcinoma 39 Neuroblastoma 35 Lung Neoplasms 35 Glioblastoma 35 Carcinoma, Non-Small-Cell Lung 32 Esophageal Squamous Cell Carcinoma 29 Brain Neoplasms 28 Unspecified Adult Solid Tumor, Protocol Specific 26 Breast Neoplasms 26 Glioma 25 Adenocarcinoma Of Esophagus 25 Sarcoma 21 Gliosarcoma 20 Central Nervous System Neoplasms 20 Rhabdomyosarcoma 18 Astrocytoma 17 Sarcoma, Ewing 16 Gastrointestinal Neoplasms 15 Recurrence 13 Oligodendroglioma 13 Adenocarcinoma 13 Gallbladder Neoplasms 12

Interventions

Fulvestrant 5 Letrozole 4 exemestane 3 Capecitabine 3 Anastrozole 3 ribociclib 2 dalpiciclib 2 apatinib 2 Gemcitabine 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 pyrotinib 1 patritumab deruxtecan 1 palbociclib 1 olaparib 1 nirogacestat 1 margetuximab 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Trastuzumab 1 Tamoxifen 1 Paclitaxel 1 Neoadjuvant Therapy 1 Liposomes 1 Irinotecan 1 Ga(III)-DOTATOC 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03328884 2025-04-23

Phenomenal

MedSIR

Phase 2 Completed

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡